10.1161/CIRCRESAHA.116.308398 19
The FDA has reported 352 adverse events related to compounded GLP-1 medications overall
And it aligns naturally with how GLP-1 medications affect appetite, since most users find mornings are their least hungry period anyway
Writing to investors on Thursday, analysts at William Blair called this outcome underwhelming. Without demonstrating significant fibrosis improvement, they added, what makes pemvidutide different from other similar assets is unclear. While the Phase IIb IMPACT study met the MASH [metabolic dysfunction-associated steatohepatitis] resolution endpoint, we believe investors are considerably more interested in the other primary endpoint of fibrosis improvement, which correlates with liver failure, death and progression to cirrhosis or hepatocellular carcinoma, according to the analysts
Goes away in a few minutes
Our bodies convert it into active forms, though it is not naturally occurring